tradingkey.logo

SWK Holdings Corp

SWKH
View Detailed Chart
16.660USD
+2.260+15.69%
Close 10/10, 16:00ETQuotes delayed by 15 min
202.98MMarket Cap
11.66P/E TTM

SWK Holdings Corp

16.660
+2.260+15.69%
Intraday
1m
30m
1h
D
W
M
D

Today

+15.69%

5 Days

+13.57%

1 Month

+14.42%

6 Months

+16.62%

Year to Date

+32.65%

1 Year

+24.27%

View Detailed Chart

TradingKey Stock Score of SWK Holdings Corp

Currency: USD Updated: 2025-10-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

SWK Holdings Corp's Score

Industry at a Glance

Industry Ranking
26 / 398
Overall Ranking
81 / 4697
Industry
Banking Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
18.500
Target Price
+11.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

SWK Holdings Corp Highlights

StrengthsRisks
SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company’s segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform.
Growing
The company is in a growing phase, with the latest annual income totaling USD 44.99M.
Overvalued
The company’s latest PB is 0.82, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 10.61M shares, decreasing 2.30% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 37.20K shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

SWK Holdings Corp Info

SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company’s segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform.
Ticker SymbolSWKH
CompanySWK Holdings Corp
CEOMr. Joe D. Staggs
Websitehttps://www.swkhold.com/
KeyAI